Human CD79B Protein, His Tag (MALS verified)
分子別名(Synonym)
CD79b,B29,IGB,Ig-beta
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human CD79B, His Tag (CDB-H52H3) is expressed from human 293 cells (HEK293). It contains AA Ala 29 - Asp 159 (Accession # P40259-1).
Predicted N-terminus: Ala 29
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 17.1 kDa. The protein migrates as 30-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, 0.2 M Arginine, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
B細(xì)胞抗原受體復(fù)合物相關(guān)蛋白β鏈(CD79b)也稱為B細(xì)胞特異性糖蛋白B29、Igβ、免疫球蛋白相關(guān)B29蛋白、B29和IGB,它是一種單程I型膜蛋白,含有一個(gè)Ig樣V型(免疫球蛋白樣)結(jié)構(gòu)域和一個(gè)ITAM結(jié)構(gòu)域。CD79b需要與CD79A協(xié)同作用,以啟動(dòng)由B細(xì)胞抗原受體復(fù)合物(BCR)激活的信號(hào)轉(zhuǎn)導(dǎo)級(jí)聯(lián)。CD79b可能通過招募磷酸化CD79A的激酶或招募與CD79A結(jié)合并保護(hù)其免受去磷酸化的蛋白質(zhì)來增強(qiáng)CD79A磷酸化。CD79b的缺陷是6型無丙種球蛋白血癥(AGM6)的原因,AGM6是一種原發(fā)性免疫缺陷,其特征是由于B細(xì)胞發(fā)育的早期阻斷,血清抗體極低或缺失,循環(huán)B細(xì)胞低或缺失。
關(guān)鍵字: CD79B;CD79B蛋白;CD79B重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。